Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Catheter Precision (VTAK) EBIAT (2017 - 2025)

Catheter Precision has reported EBIAT over the past 9 years, most recently at -$5.3 million for Q4 2025.

  • Quarterly EBIAT rose 5.19% to -$5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$17.1 million through Dec 2025, down 2.69% year-over-year, with the annual reading at -$17.2 million for FY2025, 3.24% down from the prior year.
  • EBIAT was -$5.3 million for Q4 2025 at Catheter Precision, down from -$2.3 million in the prior quarter.
  • Over five years, EBIAT peaked at -$669000.0 in Q4 2023 and troughed at -$66.4 million in Q1 2023.
  • The 5-year median for EBIAT is -$5.3 million (2021), against an average of -$7.9 million.
  • Year-over-year, EBIAT plummeted 1108.37% in 2023 and then soared 95.97% in 2024.
  • A 5-year view of EBIAT shows it stood at -$6.1 million in 2021, then plummeted by 33.84% to -$8.2 million in 2022, then surged by 91.8% to -$669000.0 in 2023, then plummeted by 741.26% to -$5.6 million in 2024, then increased by 5.19% to -$5.3 million in 2025.
  • Per Business Quant, the three most recent readings for VTAK's EBIAT are -$5.3 million (Q4 2025), -$2.3 million (Q3 2025), and -$5.5 million (Q2 2025).